Summit Therapeutics (SMMT) – Research Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Summit Therapeutics (NASDAQ: SMMT) recently:

• 7/24/2026 – Summit Therapeutics was given a new $15.00 price target by Jefferies Financial Group Inc..
• 7/24/2026 – Summit Therapeutics had its price target lowered by Stifel Nicolaus from $45.00 to $38.00. They now have a “buy” rating on the stock.
• 7/24/2026 – Summit Therapeutics had its price target lowered by Guggenheim from $40.00 to $38.00. They now have a “buy” rating on the stock.
• 7/24/2026 – Summit Therapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 7/23/2026 – Summit Therapeutics had its “neutral” rating reaffirmed by HC Wainwright.
• 7/18/2026 – Summit Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 7/17/2026 – Summit Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/15/2026 – Summit Therapeutics had its “neutral” rating reaffirmed by HC Wainwright.
• 7/4/2026 – Summit Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 6/1/2026 – Summit Therapeutics had its “overweight” rating reaffirmed by KeyCorp.

Insiders Place Their Bets

In other Summit Therapeutics news, CEO Mahkam Zanganeh bought 3,810,000 shares of Summit Therapeutics stock in a transaction that occurred on Friday, June 12th. The shares were acquired at an average price of $13.12 per share, for a total transaction of $49,987,200.00. Following the acquisition, the chief executive officer owned 573,883,879 shares of the company’s stock, valued at $7,529,356,492.48. The trade was a 0.67% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Robert W. Duggan bought 3,810,000 shares of Summit Therapeutics stock in a transaction that occurred on Friday, June 12th. The shares were acquired at an average price of $13.12 per share, for a total transaction of $49,987,200.00. Following the acquisition, the chief executive officer directly owned 573,883,879 shares in the company, valued at approximately $7,529,356,492.48. This represents a 0.67% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired a total of 7,870,000 shares of company stock worth $103,616,900 over the last ninety days. 83.50% of the stock is owned by company insiders.

Summit Therapeutics plc is a clinical‐stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life‐threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies.

Summit’s lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S.